Trial Profile

A phase 2, placebo-controlled, 28-day study of PTI-428 in patients with cystic fibrosis with at least one F508del mutation

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 02 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dirocaftor (Primary) ; Nesolicaftor (Primary) ; Posenacaftor (Primary)
Indications Cystic fibrosis
Focus Adverse reactions; Therapeutic Use
Sponsors Kineta; Proteostasis Therapeutics; Yumanity Therapeutics

19 Dec 2022 According to a Kineta media release, Yumanity Therapeutics was merged with Kineta to form Kineta.
17 Dec 2019 Results presened in a Proteostasis Therapeutics Media Release.
06 Nov 2019 According to a Proteostasis Therapeutics media release, due to rapid enrollment from centers in the United States, Canada, Western Europe, and New Zealand, data from the study are now expected in the fourth quarter of 2019 instead of the first quarter of 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com